Document is current
Any future updates will be listed below
-
Authors
Unnikrishnan, Ranjit https://orcid.org/0000-0002-8587-8861
Shaw, Jonathan E. https://orcid.org/0000-0002-6187-2203
Chan, Juliana C. N. https://orcid.org/0000-0003-1325-1194
Wild, Sarah H.
Peters, Anne L.
Orrange, Sharon https://orcid.org/0000-0001-9904-617X
Roden, Michael https://orcid.org/0000-0001-8200-6382
Mohan, Viswanathan https://orcid.org/0000-0001-5038-6210
- License Information
-
More Information
Article History
Accepted: 19 June 2025
First Online: 17 July 2025
Competing interests
: V.M. has acted as consultant and speaker, and received research or educational grants from Abbott, Medtronics, Novo Nordisk, Sanofi, Servier, Boehringer-Ingelheim, Eli Lilly, Johnson & Johnson, Lifescan, Roche, MSD, Novartis, Aventis, Bayer, USV, Dr. Reddy’s, Sun Pharma, INTAS, Lupin, Glenmark, Zydus, IPCA, Torrent, Cipla, Biocon, Primus, Franco Indian, Wockhardt, Emcure, Mankind, Fourrts, Apex, GSK and Alembic. M.R. has received lecture fees or served on advisory boards for AstraZeneca, Boehringer-Ingelheim, Echosens, Eli Lilly, Madrigal, MSD, Novo Nordisk and Target RWE and has performed investigator-initiated research with support from Boehringer-Ingelheim and Novo Nordisk to the German Diabetes Center (DDZ). J.E.S. has received lecture fees or served on advisory boards for and/or received honoraria from Zuellig Pharma, AstraZeneca, Sanofi, Novo Nordisk, Eli Lilly, Abbott, Mylan, Boehringer-Ingelheim, Roche, Pfizer and GSK. R.U., S.H.W. and S.O. declare no competing interests.
